Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab

BACKGROUND: We recently reported a 56% objective response rate in patients with advanced Merkel cell carcinoma (MCC) receiving pembrolizumab. However, a biomarker predicting clinical response was not identified. METHODS: Pretreatment FFPE tumor specimens (n = 26) were stained for CD8, PD-L1, and PD-...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:J Immunother Cancer
المؤلفون الرئيسيون: Giraldo, Nicolas A., Nguyen, Peter, Engle, Elizabeth L., Kaunitz, Genevieve J., Cottrell, Tricia R., Berry, Sneha, Green, Benjamin, Soni, Abha, Cuda, Jonathan D., Stein, Julie E., Sunshine, Joel C., Succaria, Farah, Xu, Haiying, Ogurtsova, Aleksandra, Danilova, Ludmila, Church, Candice D., Miller, Natalie J., Fling, Steve, Lundgren, Lisa, Ramchurren, Nirasha, Yearley, Jennifer H., Lipson, Evan J., Cheever, Mac, Anders, Robert A., Nghiem, Paul T., Topalian, Suzanne L., Taube, Janis M.
التنسيق: Artigo
اللغة:Inglês
منشور في: BioMed Central 2018
الموضوعات:
Research Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC6167897/
https://ncbi.nlm.nih.gov/pubmed/30285852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0404-0
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة